PFE · Pfizer
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $31.50
Note written ·
Price against the kill line
9.6% clear of its kill line on the 17 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $31.50, set on 15 November 2026. The shares are up 2.3% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $31.50, over the 52-week intraday high of $31.44 set on 5 November 2026, which would show the shares leading again; or a 2027 outlook with adjusted EPS at or above the 2026 range of $2.95–3.05.
Research onlyNot in the portfolio.
Last catalyst
The business · as of
Pfizer develops, makes and sells prescription medicines and vaccines, including Eliquis, Vyndaqel, Prevnar, Padcev and Comirnaty. It sells mainly to drug wholesalers, hospitals and governments and earns money from product sales and alliance revenue. Revenue was $16,583 million in the quarter to 27 September 2026 (10-Q filed 3 November 2026).
What is changing, and what follows · as of
- What is changing now
- On 3 November 2026 Pfizer raised 2026 revenue guidance to $62.0–64.0 billion and adjusted EPS guidance to $2.95–3.05. On 11 November 2026 Blackstone Life Sciences agreed to fund up to $1.5 billion of berobenatide's development.
- What follows for the company
- Blackstone's money pays for Phase 3 obesity trials through 2028 in return for milestone payments. Pfizer plans another $2.5 billion of net savings in 2027–2029, carries $62,671 million of debt and has made no 2026 buybacks.
- What follows for its customers, suppliers and competitors
- Eli Lilly (LLY) and Novo Nordisk (NVO) face a monthly GLP-1 rival funded through Phase 3. Merck (MRK) and GSK (GSK) compete with Prevnar, down 10%, and Abrysvo. Bristol Myers Squibb (BMY) shares Eliquis.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 3 November 2026) the shares trade at 40.8 times earnings and 3.4 times sales, with a 7.2% free-cash-flow yield and an enterprise value of $216,398 million. That holds only if free cash flow stays near the $11,786 million of the four quarters to 27 September 2026 while patent-expiry losses grow in 2027.
Key figures from the filings · Health Care
Quarter to 27 September 2026, filed 3 November 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 16,583
- Revenue, change on a year (%)
- −0.4
- Gross margin (%)
- 75.7
- Free cash flow, four quarters ($M)
- 11,786
- Net cash, cash less debt ($M)
- −51,729
- Price to earnings (×)
- 40.2
- Enterprise value to sales (×)
- 3.4
- Free-cash-flow yield (%)
- 7.3
All filed numbers
What Pfizer reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) |
|---|---|---|---|
| first filed | 16,583 | −0.4 | 75.7 |
| first filed | 15,034 | +2.6 | 72.8 |
| first filed | 14,451 | +5.4 | 75.4 |
| first filed | 17,557 | −1.2 | 70.0 |
| first filed | 16,654 | −5.9 | 74.9 |
| first filed | 14,653 | +10.3 | 74.2 |
| Pre-tax income ($M) | 3,385 |
| Net income ($M) four quarters: 4,033 | 3,242 |
| Diluted shares, change on a year (%) against the quarter to 28 September 2025 | +0.6 |
| Operating cash flow ($M) | 14,173 |
| Capital spending ($M) | 2,387 |
| Free cash flow ($M) | 11,786 |
| Cash and short-term investments ($M) | 10,942 |
| Debt ($M) non-current long-term debt plus current debt | 62,671 |
| Net cash, cash less debt ($M) | −51,729 |
| Deferred revenue ($M) at 31 December 2025, filed 26 February 2026; −48.1% on a year | 784 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 14,192 |
| Inventory ($M) | 10,022 |
| Shareholders' equity ($M) | 89,001 |
| Market value ($M) | 162,275 |
| Enterprise value, market value plus net debt ($M) | 214,004 |
| Enterprise value to sales (×) | 3.4 |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | 40.2 |
| Price to book value (×) | 1.8 |
| Free-cash-flow yield (%) | 7.3 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 2.4% of shares outstanding sold short, 4.6 days of average trading to cover, −2.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Customers:
- MCK, COR, CAH
The thesis
Pfizer is more likely to lag the S&P 500 over the next three months than to lead it. The third-quarter beat and the raised guidance of 3 November 2026 are already in the price. The next test is the 2027 outlook, which Pfizer is expected to give in December 2026 as it did on 16 December 2025, and that outlook has to absorb a large rise in revenue lost to patent expiries.
The quarter was strong on its own terms. Third-quarter revenue was $16.6 billion, flat from a year earlier, but revenue excluding the COVID products Comirnaty and Paxlovid grew 7% operationally and launched and acquired products grew 32% (company 8-K, 3 November 2026). Pfizer raised 2026 revenue guidance to $62.0–64.0 billion from $60.5–62.5 billion. It also raised adjusted earnings per share (EPS) guidance to $2.95–3.05 from $2.80–3.00.
The problem is the year after. In its 2026 guidance, Pfizer put revenue lost to loss of exclusivity (generic and biosimilar entry) at more than $3 billion in 2027 and more than $6 billion in 2028, as reported by Zacks after the 16 December 2025 call. The 2026 guidance carries about $1.1 billion of that kind of loss (8-K, 3 November 2026). The shares reached a 52-week intraday high of $31.44 on 5 November 2026 and closed at $28.89 on 13 November 2026. The likelier reading is that buyers are waiting for the 2027 numbers.
The rating is Low because the bar for the December outlook is high. The case for the shares leading needs 2027 guidance that holds earnings near 2026 levels despite those losses.
Bullish and bearish views on Pfizer Inc.
The bull case on Pfizer Inc. (PFE), in brief: growth products are outrunning COVID declines. The bear case: patent-expiry losses are about to rise.
Bull case
- Growth products are outrunning COVID declines. Excluding Comirnaty and Paxlovid, third-quarter revenue grew 7% operationally, and launched and acquired products grew 32% (8-K, 3 November 2026). Padcev revenue was $720 million, up 55% from a year earlier.
- Guidance has been raised. On 3 November 2026 the revenue range moved up $1.5 billion at the midpoint to $62.0–64.0 billion. Adjusted EPS guidance moved to $2.95–3.05 and includes a one-time $650 million charge for acquired in-process research and development from the Innovent Biologics deal, worth about $0.10 a share.
- Outside money now funds the obesity trials. On 11 November 2026 Blackstone Life Sciences agreed to pay up to $1.5 billion of development costs for berobenatide, Pfizer's monthly GLP-1 injection, through 2028. Blackstone receives milestone payments tied to US approval and sales, and gets no ownership of the drug.
- The shares are cheap on cash flow. At the 13 November 2026 close the free-cash-flow yield was 7.2%, on $11,786 million of free cash flow over the four quarters to 27 September 2026 (10-Q, 3 November 2026).
- More savings are planned. Pfizer's third-quarter prepared remarks of 3 November 2026 set out another $2.5 billion of net cost savings for 2027–2029.
Bear case
- Patent-expiry losses are about to rise. Pfizer's 2026 guidance books about $1.1 billion of revenue lost to generics and biosimilars (8-K, 3 November 2026). Zacks reported Pfizer's projection that the loss will exceed $3 billion in 2027 and $6 billion in 2028.
- COVID and vaccine revenue is still falling. In the third quarter, Paxlovid fell 63% to $449 million, Comirnaty fell 30% to $808 million, and the Prevnar pneumonia-vaccine family fell 10% to $1.56 billion (8-K, 3 November 2026).
- The balance sheet limits buybacks. At 27 September 2026 Pfizer had $62,671 million of debt against $10,942 million of cash and short-term investments (10-Q, 3 November 2026). It bought back no shares in the first nine months of 2026, and its guidance assumes none for the year.
- Two analysts downgraded after the results. DZ Bank cut Pfizer to Hold from Buy on 6 November 2026. Daiwa Securities moved to Sell on 11 November 2026 and raised its target to $29 from $27, which is close to the 13 November 2026 close.
- Lilly is ahead in obesity. Eli Lilly won China approval for its oral GLP-1 weight-loss pill on 12 November 2026 (Benzinga). Berobenatide is only now entering Phase 3.
Price setup
The shares closed at $28.89 on 13 November 2026. That is above the 50-day average of $28.44 and the 200-day average of $26.20, both from adjusted daily closes as of that date. The 3-month change is +9.1%.
After the 3 November 2026 report, the shares set a 52-week intraday high of $31.44 on 5 November 2026. They closed between $28.83 and $29.45 from 6 November to 13 November 2026, through the Blackstone deal and both downgrades. The 52-week closing low is $23.67, set on 25 June 2026.
The level that matters is the 5 November 2026 high. A close back above it would show buyers paying up before the 2027 outlook. If the shares hold above the 50-day average without reaching that high, the stock is following the index while it waits for December. Measured across ten years of US stocks, there is no reliable effect so far for what happens after a sharp one-day move, a run-up or a pullback from a peak. The read here rests on the company's own results and guidance.
Catalysts ahead
- ~16 December 2026 (est.): Full-year 2027 financial guidance call, expected to follow the 16 December 2025 precedent. This settles the call. 2027 adjusted EPS guidance at or above the 2026 range would show the business absorbing patent-expiry losses; guidance below it would confirm the lag.
- ~3 February 2027 (est.): Fourth-quarter and full-year 2026 results. This shows whether Comirnaty's fourth-quarter season and the growth products kept revenue inside the raised $62.0–64.0 billion range.
Elapsed catalysts
- 17 November 2026: Chief executive Albert Bourla speaks at the Jefferies London Healthcare Conference (webcast). This is the first public chance for management to frame 2027, including patent-expiry losses and the obesity program, ahead of formal guidance. (passed)
What would change the view
A daily close above $31.50, over the 52-week intraday high of $31.44 set on 5 November 2026, which would show the shares leading again; or a 2027 outlook with adjusted EPS at or above the 2026 range of $2.95–3.05.
What it trades with
- Moves with large-cap drugmakers. Pfizer trades on the same drug-pricing and patent news as Merck (MRK), Bristol Myers Squibb (BMY) and AbbVie (ABBV). It tends to move less on news about AI or the broader economy than the S&P 500 does.
- Shares the Eliquis exposure with Bristol Myers Squibb. Eliquis brought Pfizer $2.52 billion in the third quarter, up 25% (8-K, 3 November 2026). News on this blood thinner's pricing or generic entry hits both companies.
- Obesity news from Lilly and Novo moves the pipeline view. Lilly's China approval of 12 November 2026 and data from Novo Nordisk (NVO) set the bar berobenatide's Phase 3 trials, funded by Blackstone since 11 November 2026, must clear.
- Competes with other vaccine makers. Prevnar fell 10% and Abrysvo, the RSV vaccine, rose 9% in the third quarter (8-K, 3 November 2026). The market these products serve is contested by Merck (MRK), GSK (GSK) and Moderna (MRNA).
The evidence, claim by claim (8)
- Third-quarter revenue was $16.6 billion, flat from a year earlier. Excluding Comirnaty and Paxlovid it grew 7% operationally, and launched and acquired products grew 32%. Pfizer 8-K, third-quarter 2026 results release · as of
- 2026 revenue guidance was raised to $62.0–64.0 billion from $60.5–62.5 billion. Adjusted EPS guidance was raised to $2.95–3.05 from $2.80–3.00. Pfizer 8-K, third-quarter 2026 results release · as of
- Third-quarter adjusted EPS was $0.87, including a one-time $650 million acquired in-process research and development charge for the Innovent Biologics deal. Reported diluted EPS was $0.56. Pfizer 8-K, third-quarter 2026 results release · as of
- In the third quarter, Paxlovid revenue fell 63% to $449 million, Comirnaty fell 30% to $808 million, and the Prevnar family fell 10% to $1.56 billion. Pfizer 8-K, third-quarter 2026 results release · as of
- Blackstone Life Sciences will fund up to $1.5 billion of berobenatide development costs through 2028 in return for milestone payments tied to US approval and sales, with no ownership rights. Pfizer and Blackstone Life Sciences announcement · as of
- Free cash flow was $11,786 million over the four quarters to 27 September 2026. Debt was $62,671 million and cash and short-term investments were $10,942 million. Pfizer Form 10-Q for the third quarter of 2026 · as of
- Pfizer made no share repurchases in the first nine months of 2026, with $3.3 billion of authorization remaining, and paid $1.29 a share in dividends. Pfizer 8-K, third-quarter 2026 results release · as of
- Daiwa Securities moved Pfizer to Sell and raised its target to $29 from $27. DZ Bank had cut Pfizer to Hold from Buy on 6 November 2026. Daiwa Securities rating change reported by fiscal.ai · as of
Sources
Related · shared themes
AMGN
Amgen
Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing…
REGN
Regeneron Pharmaceuticals
Regeneron's shares are modestly more likely than not to beat the S&P 500 over three months because its full Dupixent profit share lifted…
ABBV
AbbVie
AbbVie's Skyrizi and Rinvoq, each up more than 22% in the 30 October 2026 third-quarter report, keep lifting guidance and analyst targets…
GMAB
Genmab A/S
Genmab's own cancer drugs are becoming a second engine beside its DARZALEX royalty, with three launches targeted for 2027. ASH data on 14…